148 Case of Drug-Induced Liver Adverse Reactions

doi:10.19803/j.1672-8629.20250482

Abstract

Abstract: Objective To investigate the characteristics of drug-induced liver injury and provide references for related medications and prevention. Methods The case reports of drug-induced liver adverse reactions submitted to the National Adverse Drug Reaction Monitoring System by the Affiliated Hospital of Guizhou Medical University in 2021-2024 were collected and analyzed. Results A total of 148 cases of drug-induced liver adverse reactions were collected. Using the RUCAM scale, 109 cases were scored 6 to 8, and 39 cases 3 to 5. Among the 59 cases of liver injury whose detection indicators met the classification criteria, hepatocyte injury was the dominating type (44 cases), followed by the cholestatic type (10 cases) and the mixed type (5 cases). There were 55 grade Ⅰ cases and 4 grade Ⅱ cases. The top three drug categories responsible for live injury were antineoplastic drugs (41.58%), anti-infective drugs (36.63%) and drugs for the cardiovascular system (13.86%). The time from drug administration to the first detection of abnormal liver biochemical indicators was 2 to 15 days. Clinically, hepatoprotective drugs were used by 137 patients (92.57%) with drug-induced liver adverse reactions, 129 of whom provided detailed reports on their usage of hepatoprotective drugs. The types of hepatoprotective agents used ranged from 1 to 3 types: 73 cases (56.59%) took one type of hepatoprotective agent, 43 cases (33.33%) received two types of hepatoprotective agents, and 13 cases (10.08%) were given three types of hepatoprotective agents. Conclusion A wide range of drugs can cause drug-induced liver adverse reactions, with those causing hepatocellular injury as the dominating type. In clinical practice, high-risk drugs for liver injury should be monitored more rigorously. When formulating liver-protecting treatment plans, clinicians are advised to weigh the advantages and disadvantages of combined medications.

Key words: Liver, Adverse Drug Reaction, Drug-Induced Liver Injury, Antineoplastic Drugs, Anti-Infective Drugs, Cardiovascular System Drugs

CLC Number:

R994.11

TUO Kangxiu, YANG Chengli, LI Ming, JIANG Man. 148 Case of Drug-Induced Liver Adverse Reactions[J]. Chinese Journal of Pharmacovigilance, 2025, 22(10): 1154-1158.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250482

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I10/1154

References

[1] WEI Q, LI L, ZENG XQ, et al.An Analysis on Clinical Characteristics and Prognosis-Related Risk Factors in Patients with Drug-Induced Liver Injury[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2024, 32(3): 214-221.
[2] FONTANA RJ, BJORNSSON ES, REDDY R, et al.The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury[J]. Clin Gastroenterol Hepatol, 2023, 21(8): 2088-2099.
[3] LI XY, TANG JT, MAO YM.Incidence and Risk Factors of Drug-Induced Liver Injury[J]. Liver Int, 2022, 42(9): 1999-2014.
[4] The Study of Drug Induced Liver Disease of Chinese Medical Association. Diagnosis and Treatment Guideline on Drug-Induced Liver Injury[J]. Chin J Hepatol, 2015, 31(11): 1752-1769.
[5] Chinese Medical Association, Chinese Medical Association Publishing House, Study Group of Drug-Induced Liver Disease, et al. Guideline for Primary Care of Drug Induced Liver Injury: Practice Version(2019)[J]. Chin J Gen Pract, 2020, 19(10): 868-875.
[6] Chinese Medical Association, Chinese Medical Association Publishing House, Study Group of Drug-Induced Liver Disease, et al. Chinese Guideline for Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024)[J]. Chin J Gen Pract, 2024, 23(8): 813-830.
[7] CHEN XQ, JIN YY, TANG G.New Edition of Pharmacology(新编药物学)[M]. 18th Edition. Beijing: People's Health Publishing House, 2018: 13-17.
[8] LI CP.Research Progress on the Mechanism of Drug-Induced Liver Injury[J]. Chinese Remedies & Clinics(中国药物与临床), 2023, 23(6): 405-408.
[9] LI M, WANG Y, LV TT, et al.Mapping the Incidence of Drug-Induced Liver Injury: a Systematic Review and Meta-Analysis[J]. J Dig Dis, 2023, 24(5): 332-339.
[10] SUZUKI A, CHEN MJ.Epidemiology and Risk Determinants of Drug-Induced Liver Injury: Current Knowledge and Future Research Needs[J]. Liver Int, 2025, 45(4): e16146.
[11] WEERSINK RA, ALVAREZ-ALVAREZ I, MEDINA-CALIZ I, et al.Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old[J]. Clinical Pharmacology and Therapeutics, 2021, 109(4): 1147-1158.
[12] FONTANA RJ.Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives[J]. Gastroenterology, 2014, 146(4): 914-928.
[13] JIANG LS, CHEN MW.Clinical Characteristics of Liver Injury Induced by Atorvastatin[J]. Chinese General Practice(中国全科医学), 2024, 27(30): 3772-3775, 3783.
[14] Joint Committee on the Chinese Guidelines for Lipid Management. Chinese Guidelines for Lipid Management (2023)[J]. Chinese Circulation Journal(中国循环杂志), 2023, 38(3): 237-271.
[15] YANG X, TU RF, YANG JH.Clinical Characteristics and Prognosis Analysis of 498 Cases with Drug-Induced Liver Injury[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2022, 30(7): 735-740.
[16] ALLISON R, GURAKA A, SHAWA IT, et al.Drug Induced Liver Injury-a 2023 Update[J]. Toxicol Environ Health B Crit Rev, 2023, 26(8): 442-467.